Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio's stock has fallen by 40%, presenting an opportunity for investors despite cash concerns.

The biotech company's stock has been volatile in recent months, but analysts see potential in its pipeline.

Cabaletta's cash position is a concern, but analysts believe the company's clinical pipeline could drive future growth.